The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · May 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how continuous glucose monitoring (CGM) affects the health of pregnant women with gestational diabetes and their babies. Gestational diabetes is a type of diabetes that can occur during pregnancy. The researchers want to find out if using a CGM device, which continuously tracks blood sugar levels, can lead to better outcomes for both mothers and infants. They will also look at how factors like diet, income, and cultural background might influence the results.

To participate in this study, women must be at least 18 years old and have been diagnosed with gestational diabetes. Unfortunately, those who had diabetes before becoming pregnant or have certain skin allergies won't be able to join. If you qualify and decide to participate, you can expect to wear a small device that monitors your blood sugar levels over time, helping you and your healthcare team manage your condition more effectively. This study is not yet recruiting participants, but it aims to provide valuable insights into managing gestational diabetes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 years or above
• • Pregnant women diagnosed with gestational diabetes mellitus
• • Those who are willing to participate in this study
• Exclusion Criteria:
• • Those who have been diagnosed with diabetes mellitus "before pregnancy"
• • Those whose skin is likely allergic to some materials such as tapes (signs and symptoms such as redness, swelling, itching, painful, presenting blisters or rashes caused by wearing breathable tapes, patches, etc.)
• • Those who is with abnormal coagulation function